Table 4.
Changes in visual and morphological outcomes and treatment intervals over 6 months in patients with and without successful retreatment after switching to faricimab.
| All | Successfully Extended | Failed to Extend | p-Value | |
|---|---|---|---|---|
| (n = 43) | (n = 14) | (n = 29) | ||
| BCVA, logMAR | 0.00 (−0.08–0.00) | −0.05 (−0.38–0.15) | 0.00 (−0.10–0.30) | 0.003 |
| Central retinal thickness, μm | −2.0 (−36.0–25.0) | −29.0 (−51.5–−7.8) | 13.0 (−12.0–32.0) | 0.006 |
| Choroidal thickness, μm | −1.0 (−13.5–8.0) | −5.0 (−18.8–5.3) | 0.0 (−11.0–9.0) | 0.190 |
| Maximum PED, μm | −20.0 (−51.5–2.5) | −26.0 (−102.8–−13.3) | −16.0 (−33.0–9.0) | 0.080 |
| Exudative change | 0.002 | |||
| No fluid | 4 (9.3%) | 4 (28.6%) | 0 (0.0%) | |
| Reduced | 17 (39.5%) | 7 (50.0%) | 10 (34.5%) | |
| Worsened | 22 (51.2%) | 3 (21.4%) | 19 (65.5%) | |
| Extended intervals, weeks | 1.0 (0.0–3.0) | 3.0 (3.0–4.8) | 0.0 (0.0–1.0) | 0.001 |
Continuous variables are presented as medians and quartile ranges. p-values were calculated using Mann–Whitney U, Fisher’s exact, and Cochran–Armitage tests. BCVA, best-corrected visual acuity; logMAR, logarithm of the minimum angle of resolution; PED, pigment epithelium detachment.